Acute kidney injury | p | ||
---|---|---|---|
No ( N = 30) | Yes ( N = 123) | ||
Age (years) | 48.50 (31.50–64.75) | 63.00 (50.50–70.00) | 0.004 |
Male | 12 (40.0) | 93 (75.6) | < 0.001 |
G6PD deficiency | 1 (3.3) | 8 (6.5) | 0.819 |
Underlying malignancy | 0.452 | ||
Solid cancer | 0 (0) | 2 (2.3) | |
Leukemia | 13 (43.3) | 39 (31.7) | |
Non-Hodgkin lymphoma | 17 (56.7) | 73 (59.3) | |
Multiple myeloma | 0 (0.0) | 2 (1.6) | |
Other | 0 (0.0) | 7 (5.7) | |
Spontaneous TLS | 12 (40.0) | 78 (63.4) | 0.033 |
Nephrotoxic use | 6 (20.0) | 48 (39.0) | 0.082 |
Cardiovascular risk | |||
Chronic hypertension | 5 (16.7) | 41 (33.3) | 0.118 |
Diabetes | 2 (6.7) | 17 (13.8) | 0.449 |
Cardiovascular event | 2 (6.7) | 13 (10.6) | 0.763 |
Chronic kidney disease | 2 (6.7) | 8 (6.6) | 1.000 |
HIV positive status | 1 (3.3) | 25 (20.3) | 0.051 |
mSOFA score | 4.00 (2.00–4.75) | 5.00 (2.00–7.00) | 0.021 |
Vasopressors | 1 (3.3) | 23 (18.7) | 0.073 |
Mechanical ventilation | 2 (6.7) | 32 (26.0) | 0.041 |
Rasburicase use | 24 (80.0) | 90 (73.2) | 0.592 |
Laboratory data at admission | |||
Kalemia, mEq/L | 4.10 (3.70–4.70) | 4.60 (4.00–5.00) | 0.084 |
Phosphatemia, mg/dL | 3.53 (2.82–4.37) | 4.71 (3.49–6.18) | 0.003 |
Calcemia, mg/dL | 8.94 (8.17–9.48) | 8.68 (7.80–9.44) | 0.421 |
Uricemia, mg/dL | 6.84 (5.38–9.32) | 8.78 (5.17–13.10) | 0.166 |
LDH, UI/L | 2700 (2008–4630) | 2855 (1466–5286) | 0.925 |
ICU mortality | 3 (10.0) | 24 (19.5) | 0.338 |
One-year mortality | 11 (36.7) | 75 (61.0) | 0.028 |
One-year remission | 16 (53.3) | 38 (30.9) | 0.036 |